

www.infusionsolutionsinc.com

DENOSUMAB (or biosimilar) ORDER FORM	
PATIENT NAME:	DOB:HT:
ALLERGIES:	
DIAGNOSIS  THE PATIENT PREVIOUSLY RECEIVED BOND AND TAKES	
HAS THE PATIENT PREVIOUSLY RECEIVED: Denosumab?	
DIAGNOSIS:	
Infusion Solutions will select therapeutically interchangeable denosumab product based on payor requirements, product	
availability, and indication:	
1) Prolia (denosumab); 2) Jubbonti (denosumab-bbdz); 3) Wyost (denosumab-bbdz); 4) Bildyos (denosumab-nxxp); 5) Stobloco (denosumab-bmwo); 6) Conexxence (denosumab-bnht); 7) Ospomyv (denosumab-dssb)	
☐ Substitution Permitted ☐ Dispense as writ	ten (indicate brand):
MEDICATION ORDERS	
	QUENCY:
	Every 6 months
Other dose sub-Q:	Other:
PREMEDICATION: Given 15 - 30 minutes prior to injection – not typically indicated:  Diphenhydramine 25 mg PO Cetirizine 10 mg PO Acetaminophen 500 mg PO Other (dose/route): Orders are valid for 1 year. For a shorter duration, indicate here:	
STANDARD ORDERS	
ANCILLARY ORDERS:	NURSING ORDERS:
<ul> <li>Infusion Reaction Management per Infusion Solutions</li> </ul>	<ul> <li>Monitor vital signs (temp, HR, RR, BP) before and after</li> </ul>
Protocol.	therapy.
Lidocaine 1% - up to 0.2 ml intradermally PRN (may buffer	<ul> <li>Observe patient for 15 minutes after completion of therapy.</li> </ul>
with sodium bicarbonate 8.4% in 10:1 ratio). <b>LABS</b>	
LAB ORDERS:	LABS LAB FREQUENCY:
□ BMP	☐ Every 6 months at each dose
☐ Phosphorus	☐ Other:
☐ Magnesium	
☐ Other:	
-	OCCUMENTATION
REQUIRED CLINICAL DOCUMENTS:	SUPPORTING DOCUMENTS:
Baseline calcium level     RECOMMENDED CLINICAL DOCUMENTS (provide if available):	Patient demographic and insurance information     Copy of front and back of insurance cord if available.
Baseline serum creatinine	<ul><li>Copy of front and back of insurance card if available</li><li>Patient's medication list</li></ul>
Calcium and vitamin D supplementation	<ul> <li>Supporting clinical notes, including past tried and/or failed</li> </ul>
Contraceptive use and pregnancy test in all females of	therapies
reproductive potential	
<ul> <li>In patients with advanced chronic kidney disease, evaluate</li> </ul>	
for CKD-MBD	
PROVIDER INFORMATION	
PRESCRIBER SIGNATURE (substitution)	PRESCRIBER SIGNATURE (dispense as written)
PRINT NAME (FIRST AND LAST)	DATE
1/	